- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07580248
Effects of Supplementation on Performance in Football Players (FOOTBALL-TCP)
Effects of Combined Taurine, Caffeine, and Phosphatidylserine Supplementation on Physical and Cognitive Performance in Professional Male Football Players
This study investigated the effects of short-term supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players. Eighty-one players were randomly assigned to one of three groups: placebo, taurine plus caffeine, or taurine plus caffeine combined with phosphatidylserine. Supplementation was administered for 10 days, with a final dose taken 60 minutes before a standardized 105-minute football training session.
Primary and secondary outcomes included sprint performance, reaction time, GPS-derived locomotor variables, and technical and tactical performance indicators. The aim of the study was to evaluate whether combined multi-ingredient supplementation could improve performance and attenuate fatigue-related declines under match-like conditions.
Study Overview
Status
Conditions
Detailed Description
This randomized, placebo-controlled, single-blind study evaluated the effects of combined supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players.
Eighty-one participants aged 19-32 years were randomly assigned to one of three groups: placebo (lactose), taurine plus caffeine (1500 mg taurine + 200 mg caffeine), or taurine plus caffeine plus phosphatidylserine (1500 mg taurine + 150 mg caffeine + 300 mg phosphatidylserine daily for 10 days). All participants completed a 10-day supplementation period, followed by a standardized 105-minute football training session.
Outcome measures included sprint performance (30 m sprint time), reaction time (visual and auditory), GPS-derived variables (total distance, sprint activity, speed, accelerations, and decelerations), and technical and tactical performance indicators assessed by coaching staff and video analysis.
The study was conducted under controlled environmental conditions and in accordance with standardized training procedures. Data were analyzed using analysis of variance (ANOVA) with post hoc testing. The aim was to determine whether multi-ingredient supplementation could enhance performance and reduce fatigue-related declines in a football-specific setting.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Łódżkie
-
Lodz, Łódżkie, Poland, 94-020
- ŁKS Łódź
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male professional football (soccer) players
- Age 19-32 years
- Currently participating in regular team training (4-5 sessions per week)
- Medically cleared for participation in high-intensity physical activity
- Provided written informed consent
Exclusion Criteria:
- Current injury or musculoskeletal condition affecting performance
- Chronic disease or medical condition
- Use of medications that may affect physical or cognitive performance
- Regular use of dietary supplements or caffeine prior to the study period
- Smoking or alcohol consumption
- Failure to comply with study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants received a placebo (lactose) daily for 10 days.
|
Placebo (lactose) administered daily for 10 days
|
|
Experimental: Taurine + Caffeine
Participants received taurine (1500 mg) and caffeine (200 mg) daily for 10 days.
|
Taurine 1500 mg and caffeine 200 mg administered daily for 10 days
|
|
Experimental: Taurine + Caffeine + PS
Participants received taurine (1500 mg), caffeine (150 mg), and phosphatidylserine (300 mg) daily for 10 days.
|
Taurine 1500 mg, caffeine 150 mg, and phosphatidylserine 300 mg administered daily for 10 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30 m sprint time (seconds)
Time Frame: Day 10 (final training session following supplementation)
|
Time to complete a 30 meter sprint under standardized conditions, expressed in seconds; calculated as the mean of valid trials.
|
Day 10 (final training session following supplementation)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reaction time (visual and auditory)
Time Frame: Day 10 (post-supplementation)
|
Visual and auditory reaction time measured using standardized computerized reaction time tests (e.g., validated software-based assessment tools), expressed as mean response time in seconds across valid trials.
|
Day 10 (post-supplementation)
|
|
Total distance (meters)
Time Frame: Day 10 (during standardized training session)
|
Total distance covered during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters.
|
Day 10 (during standardized training session)
|
|
Running speed (m/s)
Time Frame: Day 10 (during standardized training session)
|
Mean running speed during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters per second.
|
Day 10 (during standardized training session)
|
|
Sprint count (number)
Time Frame: Day 10 (during standardized training session)
|
Total number of sprint efforts recorded during the standardized training session using GPS tracking devices.
|
Day 10 (during standardized training session)
|
|
High-speed running distance (meters)
Time Frame: Day 10 (during standardized training session)
|
Distance covered at high-speed running thresholds during the standardized training session, measured using GPS tracking and expressed in meters.
|
Day 10 (during standardized training session)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sprint time decline (%)
Time Frame: Day 10 (during final training session; comparison between first and second halves)
|
Percentage decline in 30 m sprint time between the first and second halves of the standardized training session, measured using electronic timing gates and expressed as percentage change.
|
Day 10 (during final training session; comparison between first and second halves)
|
|
Running speed decline (%)
Time Frame: Day 10 (during final training session; comparison between first and second halves)
|
Percentage decline in running speed between the first and second halves of the standardized training session, measured using GPS tracking devices and expressed as percentage change.
|
Day 10 (during final training session; comparison between first and second halves)
|
|
Passing accuracy (%)
Time Frame: Day 10 (during standardized training session)
|
Percentage of successful passes during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
|
Day 10 (during standardized training session)
|
|
Dribbling success (%)
Time Frame: Day 10 (during standardized training session)
|
Percentage of successful dribbling attempts during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
|
Day 10 (during standardized training session)
|
|
Ball recoveries (number)
Time Frame: Day 10 (during standardized training session)
|
Total number of ball recoveries performed during the standardized training session, assessed using video-based performance analysis and expressed as a count.
|
Day 10 (during standardized training session)
|
|
Tactical performance score (units)
Time Frame: Day 10 (during standardized training session)
|
Coach-rated tactical performance during the standardized training session, including positioning, decision-making, and support play, assessed using a standardized rating scale and expressed in standardized score units.
|
Day 10 (during standardized training session)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Krzysztof Maciej MIZERA, PhD, 1. Vizja University in Warsaw, Faculty of Medical Sciences and Health Sciences, 01-143 Warsaw, Poland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Lipids
- Hydrocarbons, Acyclic
- Hydrocarbons
- Alkaloids
- Purinones
- Purines
- Alkanes
- Alkanesulfonic Acids
- Sulfonic Acids
- Sulfur Acids
- Membrane Lipids
- Xanthines
- Glycerophospholipids
- Phosphatidic Acids
- Glycerophosphates
- Phospholipids
- Caffeine
- Taurine
- Phosphatidylserines
Other Study ID Numbers
- MIZERA-2025-FOOTBALL-RCT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cognitive Performance
-
Texas Tech University Health Sciences CenterTexas Tech UniversityNot yet recruitingStress | Performance | Cognitive Performance | Cognitive AbilitiesUnited States
-
Ankara UniversityBurdur Mehmet Akif Ersoy UniversityCompletedAnaerobic Performance Neuromuscular Performance Cognitive PerformanceTurkey (Türkiye)
-
Atılım UniversityNot yet recruitingCognitive Performance | Physical PerformanceTurkey
-
University of MoliseGiuseppe Calcagno; Giovanni Fiorilli; Andrea Buonsenso; Alessandra di CagnoCompletedAcademic Acheivement | Cognitive Performance | Physical PerformanceItaly
-
Qassim UniversityCairo UniversityEnrolling by invitationCognitive Performance | Cognitive Performance During Physical Activity | Sustained AttentionSaudi Arabia
-
Sinop UniversityCompletedAthletic Performance | Cognitive Performance | Healthy Adult FemalesTurkey (Türkiye)
-
Inonu UniversityPrincess Nourah bint Abdulrahman University, Riyadh, Saudi ArabiaCompletedHealthy Volunteers | Cognitive Performance | Anaerobic PerformanceTurkey (Türkiye)
-
PepsiCo Global R&DCompletedSleep | Cognitive Performance | Balance | Physical PerformanceAustralia
-
The Geneva Foundation59th Medical Wing; Uniformed Services University of the Health SciencesRecruitingCognitive PerformanceUnited States
-
SeppicCompletedCognitive PerformanceBelgium
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States